Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH3: ruxolitinib versus best available therapy for steroid-refractory chronic graft-versus-host disease
NL-OMON50350Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Novartis. Primary endpoint: Overall response rate. Started Feb 2018; status: recruiting.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON50350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50350.